Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 12,200 shares, an increase of 144.0% from the December 31st total of 5,000 shares. Based on an average daily volume of 5,300 shares, the short-interest ratio is presently 2.3 days.

Clinuvel Pharmaceuticals Stock Performance

Shares of Clinuvel Pharmaceuticals stock traded down $0.02 during mid-day trading on Friday, hitting $7.65. The stock had a trading volume of 2,206 shares, compared to its average volume of 3,206. Clinuvel Pharmaceuticals has a 12-month low of $6.80 and a 12-month high of $11.40. The firm has a 50-day moving average of $7.78 and a two-hundred day moving average of $8.93.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).